Last reviewed · How we verify
American Health Research — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Guafenesin tablets | Guafenesin tablets | marketed | Expectorant | Respiratory |
Therapeutic area mix
- Respiratory · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- EMS · 1 shared drug class
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 1 shared drug class
- Liaoning University of Traditional Chinese Medicine · 1 shared drug class
- Reckitt Benckiser Inc. · 1 shared drug class
- Reckitt Benckiser LLC · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for American Health Research:
- American Health Research pipeline updates — RSS
- American Health Research pipeline updates — Atom
- American Health Research pipeline updates — JSON
Cite this brief
Drug Landscape (2026). American Health Research — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/american-health-research. Accessed 2026-05-17.